Sugi Predict

Sugi Predict / Compounds / SCHEMBL4545382

SCHEMBL4545382

SCHEMBL4545382

COC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C(CN2CCCC2)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ OPRK1 P41145 18/20 1.00
▸ OPRM1 P35372 2/20 1.00
▸ CYP3A4 P08684 1/20 1.00
▸ CYP2D6 P10635 1/20 1.00
▸ CYP2C9 P11712 1/20 1.00
▸ CYP2C19 P33261 1/20 1.00
▸ OPRD1 P41143 1/20 1.00
▸ TDP1 Q9NUW8 1/20 1.00
▸ MEN1 O00255 1/20 0.89
▸ LMNA P02545 1/20 0.89
▸ MAPK1 P28482 1/20 0.89
▸ BLM P54132 1/20 0.89
▸ KMT2A Q03164 1/20 0.89
▸ NPSR1 Q6W5P4 1/20 0.89

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29878663 1.00 OPRK1 (1.00) OPRK1OPRM1CYP3A4CYP2D6CYP2C9
SCHEMBL30456108 1.00 OPRK1 (1.00) OPRK1OPRM1CYP3A4CYP2D6CYP2C9
SCHEMBL29878034 1.00 OPRK1 (1.00) OPRK1OPRM1CYP3A4CYP2D6CYP2C9
Fumaric Acid SCHEMBL1282479 0.94 MEN1 (1.00) OPRK1OPRM1CYP3A4CYP2D6CYP2C9
Fumaric Acid SCHEMBL1282478 0.94 MEN1 (1.00) OPRK1OPRM1CYP3A4CYP2D6CYP2C9
Fumaric Acid SCHEMBL7644576 0.94 MEN1 (1.00) OPRK1OPRM1CYP3A4CYP2D6CYP2C9
Fumaric Acid SCHEMBL29878340 0.94 MEN1 (1.00) OPRK1OPRM1CYP3A4CYP2D6CYP2C9
SCHEMBL10418353 0.91 OPRK1 (1.00) OPRK1OPRM1CYP3A4CYP2D6CYP2C9
SCHEMBL8221866 0.89 OPRK1 (1.00) OPRK1OPRM1CYP3A4CYP2D6CYP2C9
SCHEMBL8221863 0.89 OPRK1 (1.00) OPRK1OPRM1CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186427-A1 METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS UNIVERSITY OF WASHINGTON 2025-06-12 — — US claimed
WO-2025095039-A1 PHARMACEUTICAL COMPOSITION FOR SKIN DISEASES, AND METHOD FOR SEARCHING NOVEL USE OF MEDICINE ティア・リサーチ・コンサルティング合同会社 2025-05-08 — — WO claimed
US-20240252484-A1 Methods and Compositions for Treating Vasomotor Symptoms UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION 2024-08-01 — — US claimed
US-20240156781-A1 CANCER THERAPEUTIC AGENT SOCIUM INC. (JP) 2024-05-16 — — US claimed
EP-4302779-A1 CANCER THERAPEUTIC AGENT Socium Inc. (JP) 2024-01-10 — — EP claimed
CN-116615242-A Cancer therapeutic agent 寿协株式会社 2023-08-18 — — CN claimed
WO-2022185952-A1 CANCER THERAPEUTIC AGENT ソシウム株式会社 2022-09-09 — — WO claimed
US-20220125781-A1 Methods and Compositions for Treating Vasomotor Symptoms UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION 2022-04-28 — — US claimed
US-4943578-A ANALGESICS; CEREBRAL ANTIISCHEMIC AGENTS GLAXO GROUP LIMITED (GB) 1990-07-24 — — US claimed
EP-0343900-A2 Piperazine compounds GLAXO GROUP LIMITED (GB) 1989-11-29 — — EP claimed
JP-2056470-A — — None — — JP disclosed
US-12637452-B2 Crystalline forms of a substituted imidazopyridine compound and use thereof as P2X3 modulator GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2026-05-26 — — US disclosed
US-20260060822-A1 BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF UNIV WAKE FOREST HEALTH SCIENCES (US) 2026-03-05 — — US disclosed
US-12527770-B2 Methods of managing pain using dexmedetomidine transdermal delivery devices TEIKOKU PHARMA USA, INC. (US) 2026-01-20 — — US disclosed
US-20250366979-A1 DEVICES AND METHODS OF MAKING AND USE THEREOF METHODIST HOSPITAL (US) 2025-12-04 — — US disclosed
EP-0974363-A1 REMEDIES FOR DRUG ADDICTION TORAY INDUSTRIES, INC. (JP) 2000-01-26 — — EP disclosed
EP-0897726-A1 ANTIPRURITIC AGENT TORAY INDUSTRIES, INC. (JP) 1999-02-24 — — EP disclosed
US-4943578-A ANALGESICS; CEREBRAL ANTIISCHEMIC AGENTS GLAXO GROUP LIMITED (GB) 1990-07-24 — — US disclosed
JP-H0256470-A PIPERAZINE COMPOUND GLAXO GROUP LTD 1990-02-26 — — JP disclosed
EP-0343900-A2 Piperazine compounds GLAXO GROUP LIMITED (GB) 1989-11-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240252484-A1 Methods and Compositions for Treating Vasomotor Symptoms VASP, PDE3A, PDE2A OPRK1 554/4885OPRM1 814/4885CYP3A4 2493/4885
US-20250186427-A1 METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS VASP, PDE3A, PDE2A OPRK1 554/4885OPRM1 814/4885CYP3A4 2493/4885
US-20260060822-A1 BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF PFKP, PBK, MYLK OPRK1 2862/4885OPRM1 4810/4885CYP3A4 2837/4885
US-12527770-B2 Methods of managing pain using dexmedetomidine transdermal delivery devices OPRD1, OPRK1, OPRM1 OPRK1 2/4885OPRM1 3/4885CYP3A4 656/4885
US-20220125781-A1 Methods and Compositions for Treating Vasomotor Symptoms VASP, PDE3A, PDE2A OPRK1 554/4885OPRM1 814/4885CYP3A4 2493/4885
US-12637452-B2 Crystalline forms of a substituted imidazopyridine compound and use thereof as P2X3 modulator P2RX3, P2RX2, P2RX4 OPRK1 37/4885OPRM1 30/4885CYP3A4 799/4885
US-20240156781-A1 CANCER THERAPEUTIC AGENT OPRK1, TUBB1, OPRL1 OPRK1 1/4885OPRM1 17/4885CYP3A4 4593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.